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Background: Serotonin 5-HT4 receptor (5-HT4-R) agonists are potential therapeutic agents for enterokinetic and
cognitive disorders and are marketed for treatment of constipation. The aim of this study was to develop an
agonist positron emission tomography (PET) ligand in order to label the active G-protein coupled 5-HT4-R in
peripheral and central tissues. For this purpose prucalopride, a high-affinity selective 5-HT4-R agonist, was selected.
Methods: [11C]Prucalopride was synthesized from [11C]methyl triflate and desmethyl prucalopride, and its LogDoct,
pH7.4 was determined. Three distinct studies were performed with administration of IV [
11C]prucalopride in male rats:
(1) The biodistribution of radioactivity was measured ex vivo; (2) the kinetics of radioactivity levels in brain regions
and peripheral organs was assessed in vivo under baseline conditions and following pre-treatment with tariquidar, a
P-glycoprotein efflux pump inhibitor; and (3) in vivo stability of [11C]prucalopride was checked ex vivo in plasma and
brain extracts using high-performance liquid chromatography.
Results: [11C]Prucalopride was synthesized in optimised conditions with a yield of 21% ± 4% (decay corrected) and a
radiochemical purity (>99%), its LogDoct,pH7.4 was 0.87. Ex vivo biodistribution studies with [
11C]prucalopride in rats
showed very low levels of radioactivity in brain (maximal 0.13% ID·g−1) and ten times higher levels in certain peripheral
tissues. The PET studies confirmed very low brain levels of radioactivity under baseline conditions; however, it was
increased three times after pre-treatment with tariquidar. [11C]Prucalopride was found to be very rapidly metabolised in
rats, with no parent compound detectable in plasma and brain extracts at 5 and 30 min following IV administration.
Analysis of levels of radioactivity in peripheral tissues revealed a distinct PET signal in the caecum, which was reduced
following tariquidar pre-treatment. The latter is in line with the role of the P-glycoprotein pump in the gut.
Conclusion: [11C]Prucalopride demonstrated low radioactivity levels in rat brain; a combination of reasons may include
rapid metabolism in the rat in particular, low passive diffusion and potential P-glycoprotein substrate. In humans,
further investigation of [11C]prucalopride for imaging the active state of 5-HT4-R is worthwhile, in view of the
therapeutic applications of 5-HT4 agonists for treatment of gastrointestinal motility disorders.
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In mammalian species, serotonin or 5-hydroxytryptamine
(5-HT) acts as a neurotransmitter and paracrine agent that
mediates a wide variety of functions, including cognitive
and emotional processes, regulation of sleep and food in-
take and cardiovascular and gastrointestinal mechanisms.
Serotonergic neurons originate in the raphé nuclei of the
brain stem and project widely to forebrain, hind brain and
spinal cord. The 5-HT is also synthesized in enterochro-
maffin cells in the gut. The latter contains 90% of the 5-
HT in the body, from where it is released in the blood to
exert a paracrine actions. To date 14 different 5-HT recep-
tors, classified into seven subclasses, have been identified.
The 5-HT1A/1B/1D/1E/1F, 5-HT2A/2B/2C, 5-HT4, 5-ht5A/5B, 5-
HT6 and 5-HT7 receptors are G-protein coupled receptors
(GPCR); the 5-HT3 receptor belongs to the class of
ligand-gated ion channels [1].
The 5-HT4 receptor (5-HT4-R) is of interest for its role
in the central nervous system (CNS) and in the peripheral
tissues. For the latter, 5-HT4-R agonists are applied thera-
peutically to treat laxative-resistant constipation [2], and
in the CNS, 5-HT4-R agonists have been shown to im-
prove memory and cognition in animal models [3,4]. In
the human brain, 5-HT4-Rs have been localized in the
basal ganglia, the hippocampal formation and the cortical
mantle [5].
A non-invasive molecular imaging technique such as
positron emission tomography (PET) could be useful to
explore the function of 5-HT4-R in vivo. To date only
[11C]SB207145, a high-affinity 5-HT4-R antagonist [6,7],
has been evaluated in large mammals and man. In gen-
eral, successful PET ligands for GPCRs are antagonists;
nevertheless, antagonists have an important disadvan-
tage. GPCRs are known to occur in interconvertible ac-
tive G-protein coupled states and in inactive uncoupled
or desensitised states. Antagonists show equal affinity
for these different GPCR states and consequently do not
distinguish between the active and the inactive receptor.
In contrast, agonists have high affinity for the active G-
protein coupled receptors and low affinity for inactive
uncoupled receptors. Therefore, agonist PET ligands will
preferentially label the activated receptors [8].
Prucalopride is a potent selective 5-HT4-R agonist [9],
currently marketed for human use for the treatment
of laxative-resistant constipation [2]. Studies with [3H]
prucalopride demonstrated favourable radioligand binding
properties in vitro [5]. Affinity was high (KD = 2 nM) and
using autoradiography in vitro [3H]prucalopride clearly la-
belled 5-HT4-R in striatum, hippocampus, frontal cortex
and substantia nigra in human brain hemispheres
cryosections [5]. Comparison of 5-HT4-R densities mea-
sured with the agonist [3H]prucalopride and with the an-
tagonist [3H]R116712 in various brain regions revealed
that B max values measured with the former, represented16% to 54% of the B max values of the latter [5]. This indi-
cates that the active G-protein coupled 5-HT4-R state may
vary between various brain regions and potentially also be-
tween peripheral tissues. This illustrates the importance of
developing an agonist 5-HT4-R PET ligand that would
allow investigating the active 5-HT4-R state in vivo.
The aim of the present study was to label prucalopride
with carbon-11, optimize its radiosynthesis and investi-
gate [11C]prucalopride in biodistribution ex vivo and





7-carboxamide monobutanedioate) and desmethyl
prucalopride (4-amino-5-chloro-N-[1-(3-hydroxypropyl)
piperidin-4-yl]-2,3-dihydro-1-benzofuran-7-carboxamide)
were provided by Shire-Movetis NV (Turnhout, Belgium).
Tariquidar, a P-glycoprotein drug efflux pump inhibitor
[10-13], was obtained from Haupt Pharma Wülfing
GmbH (Gronau, Germany). All other reagents were from
Merck (Schiphol-Rijk, The Netherlands) or Sigma-Aldrich
(Zwijndrecht, The Netherlands). They were of analytical
grade and used without further purification. High-
performance liquid chromatography (HPLC) solvents
(gradient grade) were purchased from Mallinckrodt-Baker
BV (Deventer, The Netherlands).
High-performance liquid chromatography
The semi-preparative HPLC system consisted of a Jasco
(Ishikawa-cho, Japan) PU-1587 HPLC pump, a six-way
VICI injector (VA EPC6W, VICI AG International,
Schenkon, Switzerland) with a 5-mL loop, a Jasco UV1575
UV detector, a custom made radioactivity detector and a
Phenomenex (Torrance, CA, USA) Synergi 10 μm hydro-
RP 80 C18 250 × 10 mm HPLC column; and an eluent of
methanol/0.1 M phosphate buffer (pH 4.3) 34/66 (v/v) was
used with a flow of 6 mL·min−1. Radioactivity was mea-
sured using a Veenstra (Joure, The Netherlands) VDC-405
dose calibrator. The analytical HPLC system consisted of a
Jasco PU-1580 HPLC pump, a Rheodyne 7724I injector
(IDEX Health & Science, Wertheim-Mondfeld, Germany)
with a 20-μL loop, a Jasco UV-2075 Plus UV detector, a
NaI radioactivity detector (Raytest, Straubenhardt,
Germany) and a Phenomenex Gemini 5 μm C18 150 × 4.6
mm column; and an eluent of methanol/0.1 M phosphate
buffer (pH 4.3) 30/70 (v/v) was used with at a flow of 1 mL
min−1. The peak of parent prucalopride was identified by
co-injection of a sample of cold prucalopride.
Preparation of [11C]prucalopride
The automated radiolabelling [14] of [11C]prucalopride
was performed by addition of [11C]methyltriflate [15] to
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μmol) desmethyl prucalopride and 1.9 μL (4.3 μmol)
tetrabutylammoniumhydroxide (60% solution in water)
at −25°C. After distillation and trapping of [11C]
methyltriflate, the temperature was raised to 85°C for 5
min, after which the reaction mixture was quenched
with 0.4 mL of phosphate buffer (0.1 M, pH 4.3) and di-
luted with 1.5 mL of HPLC eluent. This mixture was
subjected to semi-preparative HPLC purification. The
fraction containing [11C]prucalopride was collected and
diluted with 60 mL of sterile water.
The product was trapped by solid phase extraction using
a pre-conditioned (10 mL of ethanol followed by 10 mL of
sterile water) Waters tC18 Plus Sep PakW cartridge (Wa-
ters Chromatography BV, Etten-Leur, The Netherlands),
which was subsequently washed with 20 mL sterile water.
Next, the product was eluted from the Sep Pak cartridge
with 1 mL ethanol followed by 9 mL saline containing
7.09 mM NaH2PO4 and filtered through a sterile Millex
GV 0.22 μm membrane filter (Millipore BV, Amsterdam,
the Netherlands), using helium overpressure. Devices used
for the automated radiosyntheses were homemade [14].
The purity of the product was analysed using the analytical
HPLC system, and specific activity (SA) was determined by
HPLC based on a calibration curve (performed in triplicate
with four concentrations of parent prucalopride in the
range of 1.10−4 to 1.10−7 mol L−1) and measurement of the
ultraviolet (UV) signal.
Determination of the LogDoct,pH7.4 value of [
11C]
prucalopride
The distribution of [11C]prucalopride between 1-octanol
and 0.2 M phosphate buffer (pH 7.4) was measured in trip-
licate at room temperature by adapting a method previ-
ously described [16]. Briefly, 1 mL of 10 MBq·mL−1
solution of [11C]prucalopride in 0.2 M phosphate buffer
(pH = 7.4) was mixed vigorously with 1 mL 1-octanol for 1
min at room temperature using a vortex. After centrifuga-
tion for 5 min at 4,000 rpm and a settling period of 30 min,
five aliquots of 100 μL were taken from both layers, care-
fully avoiding cross contamination between the phases. Five
aliquots of 100 μL of the 10 MBq·mL−1 solution of [11C]
prucalopride in 0.2 M phosphate buffer (pH = 7.4) were
taken as reference for determining recovery. All aliquots
were counted for radioactivity using an automated gamma
counter, Wallac 1282 Compugamma CS (LKB Wallac,
Turku, Finland). The LogDoct,pH7.4 value was calculated
according to LogDoct,pH7.4 =
10Log(Aoct / Abuffer), with
Abuffer as the average radioactivity of five buffer samples
and Aoct as the average radioactivity of 5 1-octanol samples.
Drug solutions
[11C]prucalopride and [18F]NaF, prepared as described
previously [17], were diluted with saline to prepare anisotonic, sterile and pyrogen-free solution for IV injec-
tion. Radiochemical purity was >99%.
A tariquidar solution in 20% ethanol was diluted with
5% glucose in saline to a concentration of 7.5 mg/mL for
IV injection. The final concentration of ethanol was 10%
for the PET studies.
Animals
Experiments were performed using male Wistar rats (265 ±
15 g; Harlan Netherlands BV Horst, The Netherlands). Rats
were kept in conditioned housing under a regular light/dark
cycle (12/12 h) and allowed food and water ad libitum. All
animal experiments were in compliance with Dutch law
and approved by the VU University Animal Ethics
Committee.
[11C]prucalopride biodistribution
The biodistribution of radioactivity following IV injection
of [11C]prucalopride was measured in male Wistar rats
using a modification of the method described by Airaksinen
et al. [18]. Under 2% isoflurane anaesthesia, four groups of
four rats received an intravenous injection (tail vein) each
of [11C]prucalopride (53 ± 2 MBq at the start of the experi-
ment). Rats (four per time point) were killed, under anaes-
thesia, by cervical dislocation at 5, 15, 30 and 60 min post
injection. Whole blood was collected by cardiac puncture,
and the heart, lungs, liver, colon, kidneys and brain were ex-
cised. The following brain regions were dissected: olfactory
bulb, hippocampus, striatum, frontal and posterior cortex
(including occipital cortex), thalamic region, medulla
oblongata, cerebellum and the rest of the brain. All organs
and brain regions were weighed and counted for radioac-
tivity using an automated gamma counter. Values were
corrected for decay and the percentage of the total injected
radioactivity dose (%ID g−1) for every tissue was calculated
as percentage of the total injected radioactivity dose divided
by the weight of the tissue.
In vivo stability of [11C]prucalopride
Wistar rats (two groups of three) received an intraven-
ous injection of [11C]prucalopride (100 ± 40 MBq at the
start of the experiment) via the tail vein under 2%
isoflurane anaesthesia. At 5 and 30 min post injection,
whole blood was collected by cardiac puncture and the
brain was excised. Whole blood was centrifuged for 5
min at 4,000 rpm, and a 1-mL plasma aliquot was taken
and acidified using 10 μL of 5 M HCl and diluted with 2
mL of water. The excised brain was washed in ice-cold
saline and subsequently, one hemisphere was homoge-
nized in 12 mL ice-cold saline and centrifuged for 5 min
at 4,000 rpm. Plasma and brain extracts were passed
over Waters tC18 Plus Sep PakW cartridge (1 g, pre-
conditioned with 10 mL ethanol followed by 10 mL
water), washed with 5 mL water and eluted with 2 mL
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cartridge, were counted for radioactivity using an auto-
matic gamma counter. The methanol fraction was
analysed using the semi-preparative HPLC method for
the presence of parent [11C]prucalopride.
[11C]Prucalopride PET studies
PET system
PET measurements were performed using a high-
resolution research tomograph (HRRT) (CTI/Siemens,
Knoxville, TN, USA) scanner. The HRRT is a dedicated
human brain PET scanner, with design features that en-
able high spatial resolution combined with high sensiti-
vity, making it also suitable for small animal imaging.
This scanner has a transaxial field of view of 312 mm
and an axial field of view of 250 mm. The spatial reso-
lution ranges from 2.3 to 3.2 mm full width at half maxi-
mum (FWHM) in transaxial direction and from 2.5 to
3.4 mm FWHM in axial direction [19].
Rat treatment and PET measurements
Anaesthesia was induced and maintained by constant in-
sufflation of 1.5% to 2% isoflurane in pure oxygen into the
nose. Rats were placed in a fixation device with tooth bar
to secure a fixed and immobile horizontal position of the
head during scanning. Body temperature was kept con-
stant at 37°C with a heating pad coupled to a thermostat
which was connected to a rectal thermometer. A cannula
was inserted into the vena femoralis for radiotracer injec-
tion. Transmission measurements of 6 min duration were
performed using a 740 MBq 2D fan-collimated 137Cs mo-
ving point source.
A bolus of 10.6 ± 2.6 MBq of [11C]prucalopride was
injected IV. A 3D emission acquisition at 45-min duration
was started immediately prior to the IV injection. Four
rats underwent two consecutive PET scans at 30-min
interval. The first PET scan was performed under baseline
conditions, the second PET scan was performed following
pre-treatment with tariquidar, 15 mg·kg−1 IV given as slow
bolus 30 min prior to the [11C]prucalopride injection. At
the end of the [11C]prucalopride PET scans, [18F]NaF
(approximately 15 MBq) was injected and after 30 min,
a 30-min emission scan was acquired.
Image acquisition and reconstruction
Acquired [11C]prucalopride data were stored in 64-bit list
mode format and were subsequently histogrammed into
21 time frames of 7 × 10, 1 × 20, 2 × 30, 2 × 60, 2 × 150
and 7 × 300 s duration. The [18F]NaF data were stored as
a single 30-min frame. All data were normalized and
corrected for attenuation, randoms, scatter, decay and
dead-time. Data were reconstructed using 3D ordered
subsets-weighted least squares (3D-OSWLS) [20] using
seven iterations and 16 subsets. The image matrix was256×256×207 voxels with a voxel size of 1.218 × 1.218 ×
1.218 mm3.PET data analysis
Region of interest analysis [18F]NaF scans of the brain
were co-registered with a standard MR template to de-
lineate regions of interest (ROIs) as previously described
[21]. The following ROIs were used: striatum (30 mm3),
hippocampus (27 mm3), frontal plus parietal cortical
area (49 mm3), posterior plus occipital cortical area (49
mm3), and cerebellum (86 mm3). Peripheral ROIs of the
heart, liver, small intestine (jejunum and ileum), colon,
and the caecum were manually drawn directly into the
dynamic PET images. ROIs were transferred onto the
dynamic PET images, and regional time activity curves
(TACs in kBq·mL−1) were generated [22].Binding potential quantification The simplified refer-
ence tissue model [23], with cerebellum as reference tis-
sue, was used to calculate non-displaceable binding
potential (BPND) as outcome measure of specific binding
in the analysed brain regions [24].Statistical analysis Differences in BPND values between
baseline and post tariquidar scans were tested using a
general linear mixed model in SPSS Statistics (version
17.0; SPSS Inc., Chicago, IL, USA). All results are
expressed as mean ± standard deviation (SD), and values
of p < 0.05 were considered to be statistically significant.Results
Radiolabelling and automated synthesis of [11C]
prucalopride
Optimized radiosynthesis of [11C]prucalopride (Figure 1)
followed by preparative purification on HPLC, isolation by
solid phase extraction and formulation, yielded 1.1 to 1.3
GBq of formulated [11C]prucalopride. Total preparation
time was 45 ± 5 min, yield 21% to 25%, radiochemical pur-
ity >99% and SA 52 ± 19 GBq·μmol−1. Radiochemical yields
for several reaction conditions and parameters investigated
are presented in Table 1. These yields are decay corrected
and either determined by analysing samples taken from the
reaction mixture (analytical yields) or from activities at the
start of synthesis and in the formulated product.
The methylation reaction occurred with significant for-
mation of side-product. In addition, there was a significant
amount of unreacted [11C]methyl triflate (Figure 2). For-
mation of [11C]prucalopride was confirmed by analytical
HPLC using co-injection of reference prucalopride. Repre-
sentative chromatograms of both semi-preparative and
analytical HPLC purification are shown in Figure 2.
Figure 1 Chemical structures of desmethyl prucalopride and [11C]prucalopride. Optimized reaction conditions and reagents for the
radiosynthesis are as follows: [11C]methyl triflate, CH3CN, TBAOH, 5 min and 85°C.
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11C]prucalopride
The measured LogDoct,pH7.4 value of [
11C]prucalopride
was 0.870 ± 0.004 (n = 3). The recovery of radioactivity
in the sum of 1-octanol and phosphate buffer fractions
was 94.1% ± 1.7%.[11C]prucalopride biodistribution studies
The biodistribution of radioactivity after IV injection of
[11C]prucalopride in rats was determined ex vivo in brain
regions, peripheral organs and blood at 5, 15, 30 and 60
min. Results are presented in Table 2. At 5 min post IV in-
jection of [11C]prucalopride, low levels of radioactivity in
brain were observed, the highest percentage of the total
injected radioactivity dose value being 0.13 in the olfactory
bulb. Levels of radioactivity in olfactory bulb, striatum and
hippocampus were higher than in cortical areas, thalamus,
medulla oblongata, cerebellum and the rest of the brain.
Over time, radioactivity in brain areas fluctuated over the
60 min, and a decrease of 60% to 70% was observed. In
the peripheral tissues, radioactivity levels at 5 min were
highest in the kidney followed by the liver and lung; how-
ever, the level was lower in the colon and very low in the
heart and blood. Radioactivity in the kidney and lung wasTable 1 Overview of parameters investigated to optimize rad












For every reaction, CH3CN was used as solvent; the reaction volume was 350 μL an
analysing samples taken from the crude reaction mixture (analytical yields) or deter
product (preparative yields).reduced to 1/3 at 15 min. The disappearance of radioactiv-
ity with time was slower for other tissues and, in particular,
in the liver.In vivo stability of [11C]prucalopride in rats
In vivo stability of [11C]prucalopride was measured at 5
and 30 min post IV injection of [11C]prucalopride, by
analysing the presence of the parent compound in
plasma and brain methanol extracts using HPLC. The
complete procedure was performed with a radioactivity
recovery of >90%. Most of the radioactivity was recov-
ered in the water fraction of the Seppak, which would be
polar radiolabelled metabolites of [11C]prucalopride;
however, these products were not identified. The metha-
nol extract of the Seppak column, expected to contain
parent [11C]prucalopride, contained no parent com-
pound for both plasma and brain extracts taken at 5 and
30 min post injection.
[11C]prucalopride PET studies in rats
Following IV injection of [11C]prucalopride at baseline
conditions, all rats showed low cerebral levels of radio-
activity. Radioactivity levels were highest at 30 s, and foriosynthesis of [11C]prucalopride
) Temp (°C) Methylation agent Yield (%) Yielda Number
25 [11C]CH3I 0 Analytical 1
85 [11C]CH3I 1 Analytical 1
25 [11C]CH3I 6 Analytical 1
85 [11C]CH3I 7 Analytical 1
25 [11C]CH3I 11 ± 1 Analytical 2
85 [11C]CH3I 12 ± 1 Analytical 2
85 [11C]methyl triflate 12 ± 0 Analytical 2
85 [11C]methyl triflate 16 ± 0 Preperative 2
85 [11C]methyl triflate 31 ± 2 Preperative 2
85 [11C]methyl triflate 32 ± 1 Preperative 2
85 [11C]methyl triflate 34 ± 3 Preperative 14
d the reaction time was 5 min. aThe presented yields are either determined by
mined from the activity at start of synthesis and the activity in the formulated
Figure 2 Representative HPLC chromatograms of the purification of the reaction mixture and formulated [11C]prucalopride. (A)
Chromatograms of the semi-preparative HPLC purification of the reaction mixture. (A1) UV vs. time; (A2) radioactivity vs. time. Retention times
were 8 min for the precursor and 11 min for [11C]prucalopride. (B) Analytical HPLC chromatograms of formulated [11C]prucalopride vs. time. (B1)
UV vs. time; (B2) radioactivity vs. time; (B3) UV spiked with cold prucalopride. Retention times were 8.5, 8.8 and 8.5 min for UV, radioactivity signal
of [11C]prucalopride and UV spiked with cold prucalopride, respectively. UV and radioactivity detections were connected in series, giving a time
delay of 0.3 min.
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0.6, which was declined to ≤0.3 at 40 min (Figure 3).
In all animals, tariquidar pre-treatment resulted in
higher cerebral concentrations of radioactivity following
the IV injection of [11C]prucalopride than at baseline. Infact, brain radioactivity concentrations were approxi-
mately three-fold higher in all brain regions with a peak
SUV of 1.3 ± 0.2, which subsequently declined to SUVs ≤
1 within 20 min (Figure 3). Representative PET images are
shown in Figure 4.
Table 2 Distribution of radioactivity in several brain regions and peripheral organs in rats
Organ/region Percentage ID/g (mean ± SD, n = 4 per time point)
5 min 15 min 30 min 60 min
Olfactory bulb 0.13 ± 0.04 0.05 ± 0.03 0.10 ± 0.05 0.04 ± 0.01
Striatum 0.07 ± 0.01 0.05 ± 0.02 0.08 ± 0.05 0.04 ± 0.01
Hippocampus 0.09 ± 0.02 0.05 ± 0.02 0.05 ± 0.01 0.03 ± 0.01
Medulla oblongata 0.06 ± 0.00 0.03 ± 0.01 0.05 ± 0.00 0.03 ± 0.00
Frontal cortex 0.06 ± 0.00 0.03 ± 0.02 0.03 ± 0.00 0.02 ± 0.00
Thalamic region 0.05 ± 0.00 0.03 ± 0.01 0.03 ± 0.01 0.02 ± 0.01
Posterior cortex 0.06 ± 0.01 0.04 ± 0.02 0.03 ± 0.01 0.03 ± 0.01
Rest of the brain 0.06 ± 0.00 0.03 ± 0.02 0.05 ± 0.00 0.03 ± 0.00
Cerebellum 0.08 ± 0.01 0.04 ± 0.02 0.04 ± 0.00 0.02 ±0.00
Liver 1.60 ± 0.58 1.32 ± 0.59 1.53 ± 0.19 0.83 ± 0.05
Kidney 2.57 ± 0.24 1.06 ± 0.49 0.79 ± 0.10 0.43 ± 0.04
Lungs 1.55 ± 0.61 0.51 ± 0.23 0.39 ± 0.13 0.24 ± 0.04
Colon 1.01 ± 0.29 0.54 ± 0.26 0.32 ± 0.07 0.22 ± 0.03
Heart 0.39 ±0.04 0.21 ± 0.10 0.19 ± 0.01 0.10 ± 0.01
Blood 0.16 ± 0.01 0.08 ± 0.04 0.10 ± 0.01 0.06 ± 0.00
Radioactivity is measured ex vivo at various time points following IV injection of 53 ± 2 MBq (SA 42 ± 8 GBq·μmol−1) of [11C]prucalopride. Tissue samples were not
flushed with saline prior to the radioactivity measurement. Experiments were performed on two separate days, day 1 at 5 and 15 min and day 2 at 30 and
60 min.
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cortex, posterior cortex and medulla oblongata, using
cerebellum as reference tissue, are shown in Table 3. At
baseline, BPND values were essentially zero. Following
tariquidar pre-treatment, however, positive BPND values
were obtained for the striatum and hippocampus.
The representative whole body PET images following
IV injection of [11C]prucalopride at baseline and after
pre-treatment with tariquidar (15 mg·kg−1 IV) are shown
in Figure 5. High levels of radioactivity over time
(summed image 0 to 45 min) were seen in the bladder,
liver, jejunum, colon, and caecum (the beginning of the
colon). Time activity curves based on SUV values in se-
lected tissues are shown in Figure 6. The hearth showed
high SUV values (maximal SUVs of 10.4 ± 1.3) only
within the first minute after IV injection of [11C]
prucalopride, whereafter SUV values were <1. Tariquidar
pre-treatment did not affect the time activity curve of SUV
values in the heart. In liver a maximal SUV of 4.6 ± 0.8 was
observed at 8.75 min post injection which slowly declined
over time. Pre-treatment with tariquidar afforded lower
maximal SUVs of 3.6 ± 0.4 which declined to 2.8 ± 0.3 at
the end of the scan. Radioactivity levels in the small intes-
tine were initially higher for baseline compared to post
tariquidar treatment, after 12.5 min SUVs were approxi-
mately 3.3 under both conditions and remained constant
over time. For the colon, levels of radioactivity under base-
line were maximal at 17.5 min with SUVs of 3.1 ± 1.6
which declined to SUVs of 2.5 ± 0.4 at the end of the scan.
Post tariquidar colon SUVs were approximately 1.8 overtime. The ROI placed on the caecum showed that SUVs, at
baseline conditions, increased to maximal SUVs of 9.6 ±
6.2 at 27.5 min post injection. Post tariquidar measure-
ments afforded SUVs of approximately 3.5, which remained
constant over time.
Discussion
Radiolabelling and automated synthesis
Radiolabelling of [11C]prucalopride was performed using
both [11C]CH3I and [
11C]methyl triflate. Using NaOH as
a base, [11C]CH3 incorporation was low and labelled side
products (80% to 90%) were formed primarily. Using
TBAOH as the base resulted in less side products and
incorporation of [11C]CH3 of 7% to 11%, possibly due to
the reduced deprotonation of the secondary amine
group of the precursor. Using [11C]methyl triflate and
still lower amounts of TBAOH further increased [11C]
CH3 incorporation. Optimal conditions were achieved
with 1.5 to 1.6 molar equivalents of base, resulting in an
incorporation yield of 30% to 36% of [11C]CH3. Using
these optimal conditions, automated radiosynthesis
resulted in a formulated product with a total yield of
21% ± 4% (decay corrected) at the end of an overall
preparation time of 45 ± 5 min, with good specific activity
and high radiochemical purity.
LogDoct, pH7.4 value of [
11C]prucalopride
LogD was used as parameter for lipophilicity rather than
LogP, as LogP relates to lipophilicity for the charge-
neutral form of the radioligand only, whilst LogD takes
Figure 3 Time-activity curves in various brain regions, following IV injection of 15±4 MBq [11C]prucalopride. Time-activity curves in
various brain region, measured using PET, following IV injection of 15 ± 4 MBq [11C]prucalopride (SA 65 ± 5GBq·μmol−1). Open triangles (with
dashed line) represent SUVs at baseline, and solid triangles (with solid line) represent SUVs after tariquidar pre-treatment (15 mg·kg−1 IV). In both
cases n = 4.
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prucalopride that contains a primary, secondary and ter-
tiary amine functions at a physiological pH of 7.4 [25].
The measured LogDoct,pH7.4 value of 0.87, corresponding
to a distribution ratio of 7.76 between 1-octanol and
phosphate buffer of pH 7.4, points to a relatively lowlipophilic nature of prucalopride. Pike reported in 2009
that PET ligands with moderate lipophilicity indicated
by logDoct,pH7.4 values in the range of 2.0 to 3.5 showed
optimal passive brain entrance. Exceptionally, some use-
ful radiotracers with lower or higher logDoct,pH7.4 values
also entered the brain, but mostly for unclear reasons
Figure 4 Summed (0 to 20 min after injection) [11C]prucalopride images. (left) baseline, (middle) baseline co-registered with MR template
and (right) following tariquidar (15 mg·kg−1 IV) predosing. Arrows indicate the (a) eye, (b) Harderian gland and (c) brain.
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hamper its passive diffusion into the brain.[11C]prucalopride stability in vivo
In this in vivo stability study in rats, the parent [11C]
prucalopride was not detectable in the blood and brain ex-
tracts, at 5 or 30 min following IV injection; whereas dif-
ferent radiolabelled products were detected at both time
points. This confirms the findings of previous studies,
showing that in male rats, prucalopride is extensively
metabolised, reportedly through hydroxylation and/or
O-demethylation. Such extensive metabolism was not seen
in other species (Shire-Movetis, unpublished results; partly
reported in [27]). In this study, hydroxylation of [11C]
prucalopride would yield a radiolabelled metabolite
which is highly hydrophilic (cLogP 0.007) and is thus
expected not to pass the blood-brain barrier readily. O-de-
methylation of [11C]prucalopride by CYP1A2 and other
isoenzymes in the liver [28-30] would yield unlabelled hy-
droxylated prucalopride and [11C]CH3OH and possibly
[11C]CH2O. Formation of the latter was demonstrated in
different enzymatic de-methylation reactions and it was
found that CH2O formed in tissue, readily and sponta-
neously forms condensation products e.g., with aryle-
thylamines, such as catecholamines and indoleamines
[31,32]. [11C]CH3OH and condensation products of [
11C]
CH2O may have contributed to nonspecific levels of radio-
activity in the brain and peripheral tissues.Table 3 BPND for [
11C]prucalopride in rat brain regions
versus cerebellum
Brain region Baseline Tariquidar pre-treatment
Striatum 0.00 ± 0.08 0.07 ± 0.09**
Hippocampus −0.05 ± 0.05 0.07 ± 0.05*
Frontal cortex 0.04 ± 0.07 0.03 ± 0.04
Posterior cortex 0.00 ± 0.05 0.03 ± 0.04
BPND for [
11C]prucalopride in rat brain regions, at baseline and following pre-
treatment with tariquidar (n = 4 for both conditions). Significant difference
compared with baseline: *p < 0.05, **p < 0.01.Is [11C]prucalopride a potential PET ligand?
Rats, commonly used and readily available species for ini-
tial evaluation of potential PET ligands, were also used for
the present ex vivo biodistribution and in vivo PET studies.
Unfortunately, evaluation of [11C]prucalopride as a poten-
tial PET ligand in the rat was hampered by rapid metabol-
ism, in which the male rat is much faster than in other
species [27]. Nevertheless, some interesting findings were
made. Information was obtained that can explain the low
radioactivity levels in the brain of [11C]prucalopride in this
study. In rats, the brain levels of radioactivity following IV
injection of [11C]prucalopride was extremely low and
under baseline conditions probably represented minute to
no parent [11C]prucalopride, due to the fast metabolism.
Surprisingly, the following pre-treatment with tariquidar
levels of radioactivity in all brain areas was increased
three-fold within seconds after IV injection of [11C]
prucalopride (Figure 3). Tariquidar is an inhibitor of the P-
glycoprotein ABC transporter. This transporter is located
in capillary endothelial cells of the blood-brain barrier,
where its function is to translocate xenobiotics out of the
brain and in the intestinal epithelium, where it translo-
cates toxic metabolites and xenobiotics from the cells and
blood into the intestinal lumen [33,34]. Tariquidar is also
an inhibitor of CYP1A2, an enzyme involved in the metab-
olism of prucalopride. Therefore, increased levels of radio-
activity in the brain following tariquidar pre-treatment
could be a result of slower metabolism and/or higher
blood concentrations of unchanged [11C]prucalopride. On
the other hand, it may also indicate that prucalopride is a
P-glycoprotein substrate and that its removal from the
brain is reduced by inhibition of the pump. The extremely
fast appearance of the effect could suggest that the ra-
dioactivity that appears in the brain within seconds after
injection represents for the major part parent [11C]
prucalopride. Hence, low levels of radioactivity in rat brain
under baseline conditions could be due to (1) rapid me-
tabolism, in particular in male rats, (2) limited passive dif-
fusion owing to its low lipophilicity, and (3) the possibility
of being a P-glycoprotein substrate. In a pilot PET study in
one pig, the parent compound was detected in the blood
Figure 5 Summed (0 to 45 min after injection) whole body PET images following IV injection of [11C]prucalopride in rat. (left) Baseline
and after (right) pre-treatment with tariquidar (15 mg·kg−1 IV). Arrows indicate the (a) brain region, (b) lungs, (c) spine, (d) stomach, (e) liver, (f)
jejunum, (g) caecum, and (h) bladder.
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vation), supporting the low brain uptake of [11C]
prucalopride .
Radioactivity levels in peripheral tissues following IV in-
jections of [11C]prucalopride were substantially higher than
in the brain, as shown in both the ex vivo biodistribution
and in the in vivo PET study. PET images in the gut deserve
particular attention in view of the therapeutic application of
prucalopride in gastrointestinal motility disorders. In this
rat PET study, the caecum could clearly be delineated, al-
though no analysis was done on the identity of the radio-
activity in the gut. SUV values in the caecum and colon as
a whole were reduced after tariquidar pre-treatment as
compared to the baseline. This is in line with the role of the
P-glycoprotein pump in the gut [35]. If prucalopride is a
P-glycoprotein substrate, its transport from blood into theintestinal lumen should indeed be reduced by inhibiting
P-glycoprotein.
5-HT4-R has been localized in the colonic mucosa and
circular muscles [36]. As prucalopride is used to treat con-
stipation, the ability to investigate the active state of 5-HT
4-R in the colon and the intestine in general, in vivo,
would be highly interesting. It could provide information
on the active 5-HT4-R, for example, in cases of reduced
gastric motility and it would allow monitoring possible
5-HT4-R desensitisation during treatment with 5-HT4-R
agonists. Further evaluation of [11C]prucalopride as a po-
tential agonist PET ligand for 5-HT4-R in humans, where
prucalopride is slowly metabolised [2], seems worthwhile.
In human studies, the labelling of peripheral 5-HT4-R
could be fully explored and the uptake into the brain
could be further checked.
Figure 6 Time activity curves in selected peripheral tissues following IV injection of 15±4 MBq [11C]prucalopride. Time activity curves in
selected peripheral tissues following IV injection of 15 ± 4 MBq [11C]prucalopride (SA 65 ± 5 GBq·μmol−1). Open triangles (with dashed line)
represent SUVs at baseline; solid triangles (with solid line) represent SUVs after tariquidar pre-treatment (15 mg·kg−1 IV). Data represent mean ±
SD (n = 4).
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[11C]prucalopride was successfully synthesized. How-
ever, because of its extremely fast metabolism, the male
rat appeared not an appropriate species to assess the
value of [11C]prucalopride as PET ligand. Because oflow lipophilicity and the possibility of it being a P-
glycoprotein substrate, [11C]prucalopride may not be
suitable for in vivo imaging of central 5-HT4-R. How-
ever, further investigation of [11C]prucalopride for im-
aging the active state of 5-HT4-R, in particular, in
Buiter et al. EJNMMI Research 2013, 3:24 Page 12 of 13
http://www.ejnmmires.com/content/3/1/24human, is worthwhile in view of therapeutic applica-
tions of 5-HT4 agonists for the treatment of gastro-
intestinal motility disorders.
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